Patienter, hvis HIV- 1 udtrykte 3 eller flere tymidinanalog- forbundne mutationer (TAMer), som omfattede enten en M41L - eller en L210W- substitution i RT, udviste reduceret følsomhed over for tenofovirdisoproxilfumarat.
Patients with HIV-1 expressing three or more thymidine analogue associated mutations (TAMs) that included either an M41L or an L210W substitution in RT showed reduced susceptibility to tenofovir disoproxil fumarate.